140 related articles for article (PubMed ID: 36480783)
1. BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for
Sun J; Chu F; Pan J; Zhang Y; Yao L; Chen J; Hu L; Zhang J; Xu Y; Wang X; Cao W; Xie Y
J Clin Oncol; 2023 Feb; 41(5):991-999. PubMed ID: 36480783
[TBL] [Abstract][Full Text] [Related]
2. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.
Su L; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2020 Jun; 146(12):3335-3342. PubMed ID: 32037537
[TBL] [Abstract][Full Text] [Related]
3. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.
Akdeniz D; van Barele M; Heemskerk-Gerritsen BAM; Steyerberg EW; Hauptmann M; ; van de Beek I; van Engelen K; Wevers MR; Gómez García EB; Ausems MGEM; Berger LPV; van Asperen CJ; Adank MA; Collée MJ; Stommel-Jenner DJ; Jager A; Schmidt MK; Hooning MJ
Breast; 2022 Feb; 61():98-107. PubMed ID: 34929424
[TBL] [Abstract][Full Text] [Related]
4. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
van den Broek AJ; van 't Veer LJ; Hooning MJ; Cornelissen S; Broeks A; Rutgers EJ; Smit VT; Cornelisse CJ; van Beek M; Janssen-Heijnen ML; Seynaeve C; Westenend PJ; Jobsen JJ; Siesling S; Tollenaar RA; van Leeuwen FE; Schmidt MK
J Clin Oncol; 2016 Feb; 34(5):409-18. PubMed ID: 26700119
[TBL] [Abstract][Full Text] [Related]
5. Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients.
Lin PH; Chen SC; Tseng LM; Chang KJ; Huang AC; Cheng KC; Yang K; Wu HC; Chao TY; Chang YC; Lin PC; Kuo WH; Kuo WL; Lin CH; Chen HM; Yeh DC; Liu LC; Liu CY; Wang MY; Lo C; Lu YS; Huang CS
Breast Cancer Res Treat; 2022 Apr; 192(3):629-637. PubMed ID: 35113257
[TBL] [Abstract][Full Text] [Related]
6. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
Bernstein JL; Thomas DC; Shore RE; Robson M; Boice JD; Stovall M; Andersson M; Bernstein L; Malone KE; Reiner AS; Lynch CF; Capanu M; Smith SA; Tellhed L; Teraoka SN; Begg CB; Olsen JH; Mellemkjaer L; Liang X; Diep AT; Borg A; Concannon P; Haile RW;
Eur J Cancer; 2013 Sep; 49(14):2979-85. PubMed ID: 23706288
[TBL] [Abstract][Full Text] [Related]
7. Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis.
Molina-Montes E; Pérez-Nevot B; Pollán M; Sánchez-Cantalejo E; Espín J; Sánchez MJ
Breast; 2014 Dec; 23(6):721-42. PubMed ID: 25467311
[TBL] [Abstract][Full Text] [Related]
8. Prediction and clinical utility of a contralateral breast cancer risk model.
Giardiello D; Steyerberg EW; Hauptmann M; Adank MA; Akdeniz D; Blomqvist C; Bojesen SE; Bolla MK; Brinkhuis M; Chang-Claude J; Czene K; Devilee P; Dunning AM; Easton DF; Eccles DM; Fasching PA; Figueroa J; Flyger H; García-Closas M; Haeberle L; Haiman CA; Hall P; Hamann U; Hopper JL; Jager A; Jakubowska A; Jung A; Keeman R; Kramer I; Lambrechts D; Le Marchand L; Lindblom A; Lubiński J; Manoochehri M; Mariani L; Nevanlinna H; Oldenburg HSA; Pelders S; Pharoah PDP; Shah M; Siesling S; Smit VTHBM; Southey MC; Tapper WJ; Tollenaar RAEM; van den Broek AJ; van Deurzen CHM; van Leeuwen FE; van Ongeval C; Van't Veer LJ; Wang Q; Wendt C; Westenend PJ; Hooning MJ; Schmidt MK
Breast Cancer Res; 2019 Dec; 21(1):144. PubMed ID: 31847907
[TBL] [Abstract][Full Text] [Related]
9. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers.
Nemati Shafaee M; Goutsouliak K; Lin H; Bevers TB; Gutierrez-Barrera A; Bondy M; Arun B
Breast Cancer Res Treat; 2022 Nov; 196(1):143-152. PubMed ID: 36006499
[TBL] [Abstract][Full Text] [Related]
11. Difference in Risk of Breast and Ovarian Cancer According to Putative Functional Domain Regions in Korean BRCA1/2 Mutation Carriers.
Park JS; Lee ST; Han JW; Kim TI; Nam EJ; Park HS
Clin Breast Cancer; 2018 Oct; 18(5):362-373.e1. PubMed ID: 29673794
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
Reding KW; Bernstein JL; Langholz BM; Bernstein L; Haile RW; Begg CB; Lynch CF; Concannon P; Borg A; Teraoka SN; Törngren T; Diep A; Xue S; Bertelsen L; Liang X; Reiner AS; Capanu M; Malone KE;
Breast Cancer Res Treat; 2010 Sep; 123(2):491-8. PubMed ID: 20135344
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.
Engel C; Fischer C; Zachariae S; Bucksch K; Rhiem K; Giesecke J; Herold N; Wappenschmidt B; Hübbel V; Maringa M; Reichstein-Gnielinski S; Hahnen E; Bartram CR; Dikow N; Schott S; Speiser D; Horn D; Fallenberg EM; Kiechle M; Quante AS; Vesper AS; Fehm T; Mundhenke C; Arnold N; Leinert E; Just W; Siebers-Renelt U; Weigel S; Gehrig A; Wöckel A; Schlegelberger B; Pertschy S; Kast K; Wimberger P; Briest S; Loeffler M; Bick U; Schmutzler RK;
Int J Cancer; 2020 Feb; 146(4):999-1009. PubMed ID: 31081934
[TBL] [Abstract][Full Text] [Related]
14. Contralateral Breast Cancer and Ipsilateral Breast Tumor Recurrence in
Yoon KH; Chae S; Kang E; Shin HC; Kim JH; Kim IA; Park SY; Kim SW; Kim EK
J Breast Cancer; 2019 Dec; 22(4):587-598. PubMed ID: 31897332
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.
Drooger J; Akdeniz D; Pignol JP; Koppert LB; McCool D; Seynaeve CM; Hooning MJ; Jager A
Breast Cancer Res Treat; 2015 Nov; 154(1):171-80. PubMed ID: 26467044
[TBL] [Abstract][Full Text] [Related]
16. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.
Reiner AS; John EM; Brooks JD; Lynch CF; Bernstein L; Mellemkjær L; Malone KE; Knight JA; Capanu M; Teraoka SN; Concannon P; Liang X; Figueiredo JC; Smith SA; Stovall M; Pike MC; Haile RW; Thomas DC; Begg CB; Bernstein JL
J Clin Oncol; 2013 Feb; 31(4):433-9. PubMed ID: 23269995
[TBL] [Abstract][Full Text] [Related]
17. The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant.
Lakeman IMM; van den Broek AJ; Vos JAM; Barnes DR; Adlard J; Andrulis IL; Arason A; Arnold N; Arun BK; Balmaña J; Barrowdale D; Benitez J; Borg A; Caldés T; Caligo MA; Chung WK; Claes KBM; ; ; Collée JM; Couch FJ; Daly MB; Dennis J; Dhawan M; Domchek SM; Eeles R; Engel C; Evans DG; Feliubadaló L; Foretova L; Friedman E; Frost D; Ganz PA; Garber J; Gayther SA; Gerdes AM; Godwin AK; Goldgar DE; Hahnen E; Hake CR; Hamann U; Hogervorst FBL; Hooning MJ; Hopper JL; Hulick PJ; Imyanitov EN; ; ; ; Isaacs C; Izatt L; Jakubowska A; James PA; Janavicius R; Jensen UB; Jiao Y; John EM; Joseph V; Karlan BY; Kets CM; Konstantopoulou I; Kwong A; Legrand C; Leslie G; Lesueur F; Loud JT; Lubiński J; Manoukian S; McGuffog L; Miller A; Gomes DM; Montagna M; Mouret-Fourme E; Nathanson KL; Neuhausen SL; Nevanlinna H; Yie JNY; Olah E; Olopade OI; Park SK; Parsons MT; Peterlongo P; Piedmonte M; Radice P; Rantala J; Rennert G; Risch HA; Schmutzler RK; Sharma P; Simard J; Singer CF; Stadler Z; Stoppa-Lyonnet D; Sutter C; Tan YY; Teixeira MR; Teo SH; Teulé A; Thomassen M; Thull DL; Tischkowitz M; Toland AE; Tung N; van Rensburg EJ; Vega A; Wappenschmidt B; Devilee P; van Asperen CJ; Bernstein JL; Offit K; Easton DF; Rookus MA; Chenevix-Trench G; Antoniou AC; Robson M; Schmidt MK
Genet Med; 2021 Sep; 23(9):1726-1737. PubMed ID: 34113011
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer treatment in mutation carriers: surgical treatment.
Biglia N; D'Alonzo M; Sgro LG; Tomasi Cont N; Bounous V; Robba E
Minerva Ginecol; 2016 Oct; 68(5):548-56. PubMed ID: 26822896
[TBL] [Abstract][Full Text] [Related]
19. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
20. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
